Gaudium IVF and Women Health Ltd Q1 FY2027 Concall Summary

Key Takeaways

• Quiet Q1, deliberate foundation-laying: Revenue grew 9.1% YoY in a seasonally weak quarter while the company front-loaded expansion costs, integrated AI embryology tools, and readied three new hubs for imminent launch.
• Reported margins cratered on a one-time marketing bet: EBITDA margin fell to 12.5% from 29% YoY, almost entirely because of a pan-India marketing push for SiD and ERICA; adjusted for one-offs, margin was a steady ~27.6%.
• AI is now live in the lab, not a pilot: SiD and ERICA became the first US-developed AI embryology tools used in a human IVF lab outside the US, integrated from 1st April, and have already lifted first-attempt clinical pregnancy rates from over 58% to 62%.
• The hub engine is turning over on schedule: South Extension opened 16th July, Gurgaon and Nagpur open within weeks, and management reaffirmed the full-year target of 10 new hubs.
• What to watch next quarter: Whether the one-time marketing spend converts into patient volume, the revenue ramp at the three new hubs, and any margin recovery toward the promised year-end steady-state.

The Q1 Margin Story: A Bet, Not a Miss

• One marketing push explains the drop: The 1,651 bps YoY margin contraction was driven by a single, pan-India campaign to aggressively market SiD and ERICA, a conscious investment to claim first-mover advantage on the technology differentiator ahead of the 27-hub roll-out.
• Adjusted performance held steady: Excluding expansion-related one-off costs, EBITDA would have been approximately ₹5.35 crores with a margin of ~27.63%, broadly in line with the steady-state operating profile.
• Pre-operational costs added weight: The quarter also absorbed pre-operational spends at South Extension, preparatory expenses for upcoming centres, incremental clinical talent hiring, and AI tool integration costs, all before any revenue from those assets.
• The payback thesis: Management expects the marketing push to generate returns throughout the rest of the year, betting that patients drawn in by the AI-led success-rate story will convert into cycles across the expanding hub network.

Dr. Manika Khanna: "This margin decline is mainly because of just one heavy marketing push that we did. This was a one-time marketing push which contributed to this difference. And this was done to basically market SiD and ERICA aggressively throughout the country. It was a pan-India exercise."

AI Embryology: From Promise to Production

• SiD and ERICA are now routine clinical practice: The two AI tools, developed by US-based IVF 2.0, were formally integrated on 1st April 2026, making Gaudium the first IVF chain in India to deploy them.
• Measurable outcome improvement: Clinical pregnancy success rate on the first attempt rose from over 58% to 62% , an approximately 8% improvement in early results where the tools were used, while cumulative pregnancy rate stands at 85%.
• How SiD works: It assesses thousands of sperm parameters in milliseconds to select the best sperm in real time, replacing the embryologist's human-eye judgment with AI-aided precision.
• Standardization is the strategic unlock: Because the tools compensate for variability in individual embryologist skill, they allow the Gaudium Signature Lab model to replicate consistent clinical quality across every new centre, regardless of location or tier.
• First-mover advantage claimed: Management explicitly framed the AI integration as a competitive moat, arguing that even small percentage-point improvements in IVF success rates translate into meaningful patient preference.

Dr. Manika Khanna: "If anyone's human skill is a bit moderate it brings it up to level. Like every doctor doesn't have the same skill, every embryologist doesn't have the same skill. So if there is any gap in human skill it overcomes that too. So this is very good for models like us which are to replicate across the country because it standardizes the precision of work."

Hub Expansion: On Track, Three About to Go Live

• South Extension opened 16th July 2026: The first milestone of the 19-centre IPO-funded expansion, housing the Gaudium Signature Lab with AI-powered embryology and internationally benchmarked quality standards.
• Gurgaon and Nagpur imminent: Gurgaon will be operational approximately 10 days from the call date (around 24th August 2026), Nagpur approximately 25 days from the call date (around 8th September 2026).
• Full-year target reaffirmed: Management remains confident of achieving the FY27 target of 10 new hubs, followed by 8 in FY28 and 1 in FY29, in line with the phase roll-out shared at listing.
• Breakeven track record: New hubs have historically broken even in three months, ahead of the stated six-month expectation, and management expects this trend to continue.
• Older assets being repositioned: Patna relocated to a better location in Kankarbagh medical hub and became operational three days before the call; Ludhiana is being supported by spoke-building across Punjab to feed patients into the hub.
• International spokes begun: Three spokes launched at Paris, Nigeria, and Sydney, with encouraging early medical tourism inquiries; international patients currently contribute 25-30% of the patient mix and that share is expected to grow.

Demand, Seasonality & the Consolidation Tailwind

• Q1 is structurally slow: Extreme heat and patient perception that injections are "heaty" suppress volumes in Q1; Q3 (festivals) is the other sluggish quarter, while Q2 and Q4 more than compensate, making this a historical pattern, not a new concern.
• Revenue growth held at 9.1% YoY despite the headwind: Higher patient volumes at major hubs, sustained traction in advanced IVF protocols, and steady international patient contribution drove the top line to ₹19.4 crores.
• The ART Act is a slow-burning consolidation catalyst: Management estimates it will take another year or so before the Act is properly enforced across states, but when it bites, the 70% unorganized segment of mushroom centres will struggle to comply with new regulations, rapidly expanding the 30% organized share.
• Patient financing widens the funnel: The HDFC Bank tie-up is helping reach patients in Tier 2 and Tier 3 markets more meaningfully, supporting the hub-and-spoke model's catchment economics.
• Pharmacy and hospital segments are margin-dilutive but strategic: They carry structurally lower margins than core IVF but strengthen the end-to-end patient journey, deepen wallet share, and reinforce the positioning as a comprehensive women's health platform.

Dr. Manika Khanna: "The mushroom centres, you know, the small centres that have opened, you must have also seen in your city or town like on every road two or three have opened. So you know, these will not be able to survive the new regulations because you really need to be working according to the regulations to survive those."

The Long-Term Vision: Beyond IVF

• Lucknow Women Hospital approved: The board has approved an estimated project cost of up to ₹15 crores , funded through internal accruals, not IPO proceeds, with commercialization expected in FY28-FY29.
• IVF remains the anchor: The IVF unit will be the bread and butter of the Lucknow facility; Lucknow was already on the IVF expansion list, so this extends rather than diverts the core strategy.
• Stretching into women's health: Management's eventual vision is to cover key areas beyond IVF, including gynaecological problems, early cancer screening, and related surgeries, arguing there is hardly any dedicated women's health facility in the country addressing this gap.
• Matured hub economics: Tier-2 cities are expected to generate approximately 30 cycles annually at maturity, while metro hubs target somewhere around 50 cycles.

Dr. Manika Khanna: "We have an eventual long-term vision that beyond IVF will, will have been and always will remain our core strength, we want to stretch a little beyond and cover certain key areas of women health."

Guidance & Commitments

Key Metrics